Top Markets
Coin of the day
Axcella Health Inc. Axcella Health Inc.

Axcella Health Inc.

AXLA
Rank in Stocks #18693
Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused... Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused on developing novel therapeutic compositions derived from endogenous metabolic modulators. These aim to address complex diseases and improve overall health. The company's primary drug candidates are AXA1665 and AXA1125. AXA1665 is currently undergoing Phase 2 clinical trials, where it is being evaluated for its potential to lower the risk of recurrent overt hepatic encephalopathy. Meanwhile, AXA1125 is progressing through multiple trials: a Phase 2b study targeting non-alcoholic steatohepatitis (NASH) treatment, and a Phase 2a study exploring its efficacy as a therapy for Long COVID patients. Founded in 2008, the entity initially operated as Newco LS16, Inc. before officially adopting the name Axcella Health Inc. in June 2016. Its operations are headquartered in Cambridge, Massachusetts.
Share Price
$4.58
Last synced: 2025-02-06
Market Cap
$189.73M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Axcella Health Inc. (AXLA)

Category

P/B ratio for Axcella Health Inc. (AXLA)
P/B ratio as of 2026 TTM: 0
According to Axcella Health Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Axcella Health Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH